SURPASS-CVOT
A Study of Tirzepatide Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 diabetes

Type of Study:
Parallel assignment in participants with type 2 diabetes and cardiovascular risk

Study Length:
about 54 months

Target Age/Sex:
over 40 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

Enroll Now

Enroll Now

Address
Address
City
State/Province
Zip/Postal
If you don't have a primary care physician, just type "Do not have a primary care physician"